#Tecentriq

Keytruda improves response rates for hard-to-treat breast cancer, but Tecentriq falls short.

Progression-free and overall survival improved in patients treated with Tecentriq plus chemotherapy.

Atezolizumab plus chemotherapy delays disease progression in people with metastatic triple-negative breast cancer.

Tecentriq plus Abraxane was approved under accelerated approval based on progression-free survival.

Tecentriq combo slows progression of hard-to-treat breast cancer.

Checkpoint inhibitor immunotherapy, alone or in combination with chemotherapy, shows promise for advanced non-small-cell lung cancer.

Tecentriq plus chemotherapy and Avastin delays disease progression and death.

Tecentriq plus chemotherapy delays disease progression or death in people with metastatic triple-negative breast cancer.

Because so few people diagnosed with SCLC survive for even a year despite treatment, an advance in survival rate is quite significant.

James Allison and Tasuku Honjo recognized for immune checkpoint discoveries.

Immunotherapy combo reduced the risk of disease progression or death in a Phase III study.

Requires use of diagnostic tests for PD-L1 levels in tumor tissue from bladder cancer patients.

Immunotherapy combo leads to longer progression-free survival.

Decreased survival seen in some metastatic bladder cancer patients treated with pembrolizumab or atezolizumab monotherapy.